Ambrisentan for the treatment of pulmonary arterial hypertension: Improving outcomes

Patient Preference and Adherence

Volumn 7, Issue , 2013, Pages 401-409

  Elshaboury, Soha M ^a   Anderson, Joe R ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Ambrisentan; Endothelin; Endothelin receptor antagonist; Letairis education and access program; Pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 2C; CYTOCHROME P450 3A4; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR ANTAGONIST; LIVER ENZYME; NIFEDIPINE; PROSTACYCLIN; SILDENAFIL; TADALAFIL; WARFARIN;

ACUTE RESPIRATORY FAILURE; DISEASE COURSE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EXERCISE TOLERANCE; FLUSHING; HEADACHE; HUMAN; MONOTHERAPY; MORTALITY; NOSE OBSTRUCTION; PATHOGENESIS; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; PROGNOSIS; PULMONARY HYPERTENSION; REGISTER; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SINUSITIS; STEADY STATE; SURVIVAL RATE; TERATOGENICITY; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 84886518672     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S30949     Document Type: Review

References (31)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343-349.
2. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:14S-34S.
3. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):5S-12S.
4. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2009;30:2493-2537.
5. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655-1665.
6. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
7. Inoue AM, Yanagisawa S, Kimura Y, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989;86:2863-2867.
8. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
9. Rubanyi GM, Polokoff PM. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994;46:325-415.
10. Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2002;165:398-405.
11. Alberts GF, Peifley KA, Johns A, Kleha JF, Winkles JA. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem. 1994;269:10112-10118.
12. Fukuroda T, Fujikawa T, Ozaki S, et al. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun. 1994;199:1461-1465.
13. Fukuroda T, Kobayashi M, Ozaki S, et al. Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol. 1994;76:1976-1982.
14. Pfizer initiates product withdrawal of THELIN® (sitaxsentan sodium) worldwide. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_ formats/pdf/medeff/advisories-avis/prof/2010/thelin_2_hpc-cps-eng.pdf. Accessed February 26, 2013.
15. Anderson JR, Nawarskas JJ. Pharmacotherapeutic management of pulmonary arterial hypertension. Cardiol Rev. 2010;18:148-162.
16. Letairis [package insert]. Foster City, CA: Gilead Sciences Inc; Oct 2012. Available from: http://www.gilead.com/pdf/letairis_pi.pdf. Accessed November 24, 2012.
17. US Food and Drug Administration. Drug approval package: Letairis (ambrisentan NDA #022081). Medical Review, Part 1. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_MedR_P1.pdf. Accessed November 11, 2012.
18. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46:529-535.
19. Gilead Sciences Inc. Prescriber Guide: Letairis and the LEAP program. Foster City, CA: Gilead Sciences Inc; Feb 2012.
20. Blankart CR, Stargardt T, Schreyögg J. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia. Pharmacoeconomics. 2011;29:63-82.
21. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010-3019.
22. Salzman SH. The 6-min walk test: clinical and research role, technique, coding, and reimbursement. Chest. 2009;135:1345-1352.
23. Wise RA, Brown CD. Minimal clinically important differences in the six-minute walk test and the incremental shuttle walking test. COPD. 2005;2:125-129.
24. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102:865-870.
25. Oudiz RJ, Galiè N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:1971-1981.
26. Blalock SE, Matulevicius S, Mitchell LC, et al. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. J Card Fail. 2010;16:121-127.
27. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther. 2012;30:93-99.
28. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18:527-539.
29. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009;135:122-129.
30. US Food and Drug Administration. FDA drug safety communication: liver injury warning to be removed from Letairis (ambrisentan) tablets. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm245852.htm. Updated 01/10/2012. Accessed September 26, 2012.
31. Tracleer [package insert]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; October 2012. Available from: http://www.tracleer.com/docs/Tracleer_Full_Prescribing_Information.pdf. Accessed December 11, 2012.